MYELODYSPLASTIC SYNDROME: DIAGNOSIS, TREATMENT AND PROGNOSIS (LITERATURE REVIEW).

细胞减少 骨髓增生异常综合症 医学 国际预后积分系统 重症监护医学 骨髓检查 体格检查 骨髓 内科学 儿科 肿瘤科
作者
S Baidurin,Sh Akhmetzhanova,A Ilmalieva,G Sagyndykova,A Orazbekova
出处
期刊:PubMed 卷期号: (334): 103-107 被引量:2
链接
标识
摘要

Given the difficulties of diagnosis, the absence of a typical clinical picture of myelodysplastic syndrome accompanied by cytopenia, a high risk of transformation into acute myeloid leukemia, discussion of the formation, terminology, pathogenesis, classification, clinical course and principles of management of this group of tumor diseases is very relevant. The review article discusses the issues of terminology, pathogenesis, classification and diagnosis of myelodysplastic syndrome (MDS), as well as the principles of management of this category of patients. Due to the absence of a typical clinical picture of MDS, in order to exclude other diseases accompanied by cytopenia, not only routine hematological examination methods are necessary, but also a mandatory cytogenetic examination of the bone marrow. Treatment of patients with MDS should be individualized, taking into account risk group stratification, age and physical status. To improve the quality of life of patients with MDS, epigenetic therapy with azacitidine has an advantage. Myelodysplastic syndrome is an irreversible tumor process with a clear tendency to transform into acute leukemia. The diagnosis of MDS is always made with caution by excluding other diseases accompanied by cytopenia. To make a diagnosis, not only routine hematological examination methods are necessary, but also a mandatory cytogenetic study of the bone marrow. The management of patients with MDS is still an unresolved problem. The approach to the treatment of MDS should be individualized and based on the patient's risk group, age, and somatic status. Epigenetic therapy has an advantage when choosing management tactics for MDS in terms of improving the quality of life of patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
云风发布了新的文献求助10
刚刚
quhayley应助古炮采纳,获得10
1秒前
1秒前
chd发布了新的文献求助10
3秒前
粗心的新之完成签到,获得积分10
4秒前
李健应助ylc采纳,获得10
5秒前
一丁雨发布了新的文献求助100
5秒前
6秒前
毛菇娘发布了新的文献求助10
9秒前
9秒前
9秒前
wzzznh完成签到 ,获得积分10
11秒前
11秒前
茵茵完成签到,获得积分10
12秒前
keyan发布了新的文献求助10
12秒前
一丁雨完成签到,获得积分10
12秒前
13秒前
qiyr发布了新的文献求助10
14秒前
15秒前
雨夜星空应助元烨华采纳,获得10
15秒前
18秒前
赵靖易完成签到,获得积分10
18秒前
18秒前
Samuel发布了新的文献求助10
18秒前
平常的毛豆应助HUO采纳,获得10
19秒前
田様应助加快步伐采纳,获得10
20秒前
雨夜星空应助元烨华采纳,获得10
21秒前
LIUZQ发布了新的文献求助10
22秒前
23秒前
24秒前
赘婿应助天天采纳,获得10
25秒前
keyan完成签到,获得积分10
25秒前
Garra9822完成签到 ,获得积分10
25秒前
Rzz发布了新的文献求助10
26秒前
领导范儿应助赵靖易采纳,获得10
26秒前
Jasper应助赵靖易采纳,获得30
26秒前
研友_VZG7GZ应助赵靖易采纳,获得10
27秒前
科研通AI5应助赵靖易采纳,获得30
27秒前
科研通AI5应助赵靖易采纳,获得10
27秒前
CodeCraft应助风趣的傲之采纳,获得10
27秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Continuum Thermodynamics and Material Modelling 2000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 1000
CRC Handbook of Chemistry and Physics 104th edition 1000
Izeltabart tapatansine - AdisInsight 600
Maneuvering of a Damaged Navy Combatant 500
An International System for Human Cytogenomic Nomenclature (2024) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3769645
求助须知:如何正确求助?哪些是违规求助? 3314713
关于积分的说明 10173349
捐赠科研通 3030002
什么是DOI,文献DOI怎么找? 1662548
邀请新用户注册赠送积分活动 795036
科研通“疑难数据库(出版商)”最低求助积分说明 756500